| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. | Cancer Res | 2009 | 2.01 |
| 2 | RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma. | Cancer Biol Ther | 2011 | 1.26 |
| 3 | MET, HGF, EGFR, and PXN gene copy number in lung cancer using DNA extracts from FFPE archival samples and prognostic significance. | J Environ Pathol Toxicol Oncol | 2009 | 1.01 |
| 4 | Critical role for the receptor tyrosine kinase EPHB4 in esophageal cancers. | Cancer Res | 2012 | 0.93 |
| 5 | Fyn is downstream of the HGF/MET signaling axis and affects cellular shape and tropism in PC3 cells. | Clin Cancer Res | 2011 | 0.87 |
| 6 | Combined MET inhibition and topoisomerase I inhibition block cell growth of small cell lung cancer. | Mol Cancer Ther | 2013 | 0.81 |
| 7 | MET/PKCbeta expression correlate with metastasis and inhibition is synergistic in lung cancer. | J Carcinog | 2009 | 0.76 |